Myeloid-Derived Suppressor-like Cells as a Prognostic Marker in Critically Ill Patients: Insights from Experimental Endotoxemia and Intensive Care Patients.
Details
Serval ID
serval:BIB_AAE7B79746C8
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Myeloid-Derived Suppressor-like Cells as a Prognostic Marker in Critically Ill Patients: Insights from Experimental Endotoxemia and Intensive Care Patients.
Journal
Cells
ISSN
2073-4409 (Electronic)
ISSN-L
2073-4409
Publication state
Published
Issued date
08/02/2024
Peer-reviewed
Oui
Volume
13
Number
4
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Publication Status: epublish
Abstract
Patients admitted to the intensive care unit (ICU) often experience endotoxemia, nosocomial infections and sepsis. Polymorphonuclear and monocytic myeloid-derived suppressor cells (PMN-MDSCs and M-MDSCs) can have an important impact on the development of infectious diseases, but little is known about their potential predictive value in critically ill patients. Here, we used unsupervised flow cytometry analyses to quantify MDSC-like cells in healthy subjects challenged with endotoxin and in critically ill patients admitted to intensive care units and at risk of developing infections. Cells phenotypically similar to PMN-MDSCs and M-MDSCs increased after endotoxin challenge. Similar cells were elevated in patients at ICU admission and normalized at ICU discharge. A subpopulation of M-MDSC-like cells expressing intermediate levels of CD15 (CD15 <sup>int</sup> M-MDSCs) was associated with overall mortality (p = 0.02). Interestingly, the high abundance of PMN-MDSCs and CD15 <sup>int</sup> M-MDSCs was a good predictor of mortality (p = 0.0046 and 0.014), with area under the ROC curve for mortality of 0.70 (95% CI = 0.4-1.0) and 0.86 (0.62-1.0), respectively. Overall, our observations support the idea that MDSCs represent biomarkers for sepsis and that flow cytometry monitoring of MDSCs may be used to risk-stratify ICU patients for targeted therapy.
Keywords
Humans, Endotoxemia, Critical Illness, Prognosis, Myeloid-Derived Suppressor Cells, Critical Care, Endotoxins, biomarker, critically ill patient, endotoxemia, hospital acquired pneumoniae, intensive care, myeloid-derived suppressor cell, sepsis
Pubmed
Web of science
Open Access
Yes
Funding(s)
SNF/Projects/310030_207418
EC/H2020/676129
EC/H2020/847422
OTHER//Fondation Carigest Promex Stiftung für die Forschung
OTHER//Société Académique Vaudoise
Create date
26/02/2024 14:43
Last modification date
12/03/2024 7:08